ABDXF (Abingdon Health) Long-Term Debt: $0.83 Mil (As of Dec. 2025)


ABDXF Abingdon Health PLC ABDXF
49 GF Score
Price $0.14
GF Value $0.24
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Abingdon Health Long-Term Debt?

Abingdon Health ABDXF +11.07% 49 Long-Term Debt is $0.83 Mil as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.24 (Possible Value Trap). The stock has 7 warning signs investors should review.

Abingdon Health's Long-Term Debt for the quarter that ended in Dec. 2025 was $0.83 Mil.

Abingdon Health's quarterly Long-Term Debt declined from Dec. 2024 ($0.94 Mil) to Jun. 2025 ($0.89 Mil) and declined from Jun. 2025 ($0.89 Mil) to Dec. 2025 ($0.83 Mil).

Abingdon Health's annual Long-Term Debt increased from Jun. 2023 ($0.89 Mil) to Jun. 2024 ($0.92 Mil) but then declined from Jun. 2024 ($0.92 Mil) to Jun. 2025 ($0.89 Mil).

Abingdon Health  (OTCPK:ABDXF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Abingdon Health Long-Term Debt Related Terms

Abingdon Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Abingdon Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abingdon Health Long-Term Debt Chart

Abingdon Health Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial 0.52 0.54 0.89 0.92 0.89

Abingdon Health Semi-Annual Data
Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.92 0.94 0.89 0.83
ABDXF
49GF Score
Abingdon Health PLC ABDXF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.83 Mil mean?
Abingdon Health (ABDXF) has a Long-Term Debt of $0.83 Mil as of Dec. 2025.
Is Abingdon Health's Long-Term Debt too high?
Abingdon Health's current Long-Term Debt is $0.83 Mil. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Long-Term Debt compare to TMO and DHR?
Abingdon Health's Long-Term Debt of $0.83 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Abingdon Health's current Long-Term Debt is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 43.8% below its estimated fair value. The current Long-Term Debt is $0.83 Mil. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Long-Term Debt is $0.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abingdon Health (ABDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued. The current stock price of $0.14 is trading 43.8% below its estimated GF Value™ of $0.24. GuruFocus considers Abingdon Health to be Possible Value Trap.

Key valuation signals for ABDXF:

  • Long-Term Debt: $0.83 Mil
  • GF Value™: $0.24 vs. price of $0.14 (43.8% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abingdon Health Business Description

Other Exchanges ABDX:UK
Address York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score

Get the complete analysis for ABDXF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$0.24
GF Value